What is DECOY THERAPEUTICS INC's earnings per share (EPS)?

DECOY THERAPEUTICS INC (DCOY) reported diluted earnings per share of $-129.10 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

DECOY THERAPEUTICS INC Financials

DCOY

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows DECOY THERAPEUTICS INC (DCOY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DCOY FY2025 2026-05-09

External financing rather than operations reset the balance sheet, while cash burn stayed far below the reported loss.

From FY2024 to FY2025, net loss widened from -$5.6M to -$12.5M even as operating cash outflow barely changed, from -$4.5M to -$4.8M. That gap means the weaker earnings figure did not translate into proportionally faster cash drain, which points to FY2025 results being shaped more by non-cash or accrual effects than by a sudden collapse in near-term liquidity.

Year-end cash rose to $10.7M from $2.4M because financing inflows of $12.3M more than covered free cash outflow of -$5.4M. Liquidity improved because the company raised capital, not because operations turned cash-generative.

With cash exceeding total liabilities at $10.7M versus $5.2M and a current ratio of 2.1x, short-term obligations look funded after the raise. At the same time, R&D fell from $7.2M in FY2023 to $368K in FY2025 while SG&A remained $3.7M, so the visible cost base has shifted away from research and toward keeping the corporate structure in place.

Financial Health Signals

Financial health score pending refresh

We are recalculating DECOY THERAPEUTICS INC's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

DECOY THERAPEUTICS INC passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

-0.39x

For every $1 of reported earnings, DECOY THERAPEUTICS INC generates $-0.39 in operating cash flow (-$4.8M OCF vs $12.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$12.6M

YoY-120.0%

DECOY THERAPEUTICS INC's EBITDA was -$12.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 120.0% from the prior year.

Net Income

$12.5M

YoY+124.4%

DECOY THERAPEUTICS INC reported $12.5M in net income in fiscal year 2025. This represents an increase of 124.4% from the prior year.

EPS (Diluted)

$-129.10

DECOY THERAPEUTICS INC earned $-129.10 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$5.4M

YoY-19.4%

DECOY THERAPEUTICS INC generated -$5.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 19.4% from the prior year.

Cash & Debt

$10.7M

YoY+339.9%

5Y CAGR-0.7%

10Y CAGR-16.7%

DECOY THERAPEUTICS INC held $10.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

8,006

DECOY THERAPEUTICS INC had 8,006 shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

212.6%

YoY-156.5pp

5Y CAGR+245.8pp

10Y CAGR+244.2pp

DECOY THERAPEUTICS INC's ROE was 212.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 156.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$368K

YoY-52.2%

5Y CAGR-44.4%

10Y CAGR-29.8%

DECOY THERAPEUTICS INC invested $368K in research and development in fiscal year 2025. This represents a decrease of 52.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$577K

5Y CAGR+194.6%

10Y CAGR+8.1%

DECOY THERAPEUTICS INC invested $577K in capex in fiscal year 2025, funding long-term assets and infrastructure.

DCOY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$0-100.0%	$1.8M-64.8%	$5.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$368K-52.2%	$770K-89.3%	$7.2M-54.7%	$15.8M+85.3%	$8.5M+23.6%	$6.9M
SG&A Expenses	$3.7M-24.9%	$5.0M-13.2%	$5.7M-19.9%	$7.1M+16.9%	$6.1M0.0%	$6.1M
Operating Income	-$12.6M-120.0%	-$5.7M+55.5%	-$12.9M+59.5%	-$31.8M-148.5%	-$12.8M-64.6%	-$7.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	N/A	N/A	N/A	N/A
Net Income	$12.5M+124.4%	$5.6M-55.5%	$12.5M+139.7%	-$31.6M-147.6%	-$12.8M-73.7%	-$7.4M
EPS (Diluted)	$-129.10	$-69.54	$-30.74	$-14.88-92.7%	$-7.72	$-0.50

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$750K	N/A	$62K-46.9%	$116K+54.1%	$76K	N/A	$137K-36.0%	$214K
SG&A Expenses	$1.5M	N/A	$833K-1.9%	$849K-48.3%	$1.6M	N/A	$869K-30.6%	$1.3M
Operating Income	-$2.3M	N/A	-$895K+7.3%	-$966K+43.8%	-$1.7M	N/A	-$1.0M+31.4%	-$1.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.2M	N/A	-$873K+8.8%	-$958K+44.0%	-$1.7M	N/A	-$972K+31.8%	-$1.4M
EPS (Diluted)	$-4.18	N/A	$-1.81-302.2%	$-0.45	$-240.07	N/A	$-11.38-380.2%	$-2.37

DCOY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$11.1M+265.8%	$3.0M-54.1%	$6.6M-55.0%	$14.7M-64.1%	$40.8M+63.8%	$24.9M
Current Assets	$11.0M+267.7%	$3.0M-54.2%	$6.5M-55.1%	$14.5M-51.9%	$30.2M+90.9%	$15.8M
Cash & Equivalents	$10.7M+339.9%	$2.4M-58.7%	$5.9M-51.3%	$12.1M-58.6%	$29.2M+162.8%	$11.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$0-100.0%	$8.9M0.0%	$8.9M
Total Liabilities	$5.2M+241.9%	$1.5M+16.3%	$1.3M-69.5%	$4.3M+102.1%	$2.1M-23.9%	$2.8M
Current Liabilities	$5.2M+241.9%	$1.5M	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.9M+289.6%	$1.5M-71.4%	$5.3M-49.1%	$10.4M-73.2%	$38.7M+74.7%	$22.2M
Retained Earnings	-$94.4M-15.3%	-$81.9M-7.3%	-$76.3M-19.7%	-$63.8M-98.2%	-$32.2M-65.7%	-$19.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$8.4M-23.8%	$11.1M+81.3%	$6.1M+337.8%	$1.4M-40.5%	$2.3M-22.6%	$3.0M-21.7%	$3.9M+8.6%	$3.6M
Current Assets	$8.4M-23.9%	$11.0M+81.1%	$6.1M+346.1%	$1.4M-41.0%	$2.3M-22.8%	$3.0M-21.8%	$3.8M+8.8%	$3.5M
Cash & Equivalents	$7.8M-27.0%	$10.7M+122.7%	$4.8M+505.1%	$795K-55.8%	$1.8M-26.1%	$2.4M-25.9%	$3.3M+0.3%	$3.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.5M-12.0%	$5.2M+179.5%	$1.8M-16.8%	$2.2M-2.4%	$2.3M+50.7%	$1.5M+61.7%	$935K-20.7%	$1.2M
Current Liabilities	$4.5M-12.0%	$5.2M	N/A	N/A	N/A	$1.5M	N/A	N/A
Long-Term Debt	$140K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.9M-34.2%	$5.9M+38.6%	$4.2M+612.0%	-$830K-1441.2%	$62K-95.9%	$1.5M-48.3%	$2.9M+23.1%	$2.4M
Retained Earnings	-$96.7M-2.4%	-$94.4M-10.5%	-$85.5M-1.0%	-$84.6M-1.1%	-$83.6M-2.1%	-$81.9M-1.8%	-$80.5M-1.2%	-$79.5M

DCOY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.8M-6.7%	-$4.5M+64.8%	-$12.8M+27.0%	-$17.6M-72.5%	-$10.2M+1.1%	-$10.3M
Capital Expenditures	$577K	$0	N/A	N/A	$0-100.0%	$3K
Free Cash Flow	-$5.4M-19.4%	-$4.5M	N/A	N/A	-$10.2M+1.1%	-$10.3M
Investing Cash Flow	$765K	$0	$0+100.0%	-$1.5M	$0+100.0%	-$3K
Financing Cash Flow	$12.3M+1064.0%	$1.1M-84.0%	$6.6M+234.1%	$2.0M-93.0%	$28.3M+59.9%	$17.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.9M-154.2%	-$1.1M+31.0%	-$1.6M-91.0%	-$862K+27.0%	-$1.2M-59.1%	-$743K+45.3%	-$1.4M-26.5%	-$1.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$965K	N/A	N/A	N/A	$0	N/A	N/A
Financing Cash Flow	$0-100.0%	$6.1M+3.6%	$5.9M+4251.3%	-$141K-125.9%	$546K+610.0%	-$107K-107.8%	$1.4M+4952.4%	-$28K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DCOY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-696.3%-547.5pp	-148.8%
Net Margin	N/A	N/A	N/A	N/A	-693.8%-553.4pp	-140.5%
Return on Equity	212.6%-156.5pp	369.1%+131.9pp	237.2%+541.5pp	-304.4%-271.4pp	-33.0%+0.2pp	-33.2%
Return on Assets	113.2%-71.4pp	184.6%-5.8pp	190.4%+406.1pp	-215.7%-184.5pp	-31.3%-1.8pp	-29.5%
Current Ratio	2.13+0.1	1.98	N/A	N/A	N/A	N/A
Debt-to-Equity	0.88-0.1	1.00+0.8	0.25-0.2	0.41+0.4	0.05-0.1	0.13
FCF Margin	N/A	N/A	N/A	N/A	-554.3%-357.2pp	-197.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-57.4%	N/A	-20.6%	N/A	-2763.3%	N/A	-33.2%+26.7pp	-60.0%
Return on Assets	-26.4%	N/A	-14.3%+54.4pp	-68.8%+4.3pp	-73.1%	N/A	-25.2%+14.9pp	-40.1%
Current Ratio	1.84-0.3	2.13	N/A	N/A	N/A	1.98	N/A	N/A
Debt-to-Equity	1.17+0.3	0.88+0.4	0.44	N/A	36.81+35.8	1.00+0.7	0.32-0.2	0.50
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is DECOY THERAPEUTICS INC profitable?

Yes, DECOY THERAPEUTICS INC (DCOY) reported a net income of $12.5M in fiscal year 2025.

What is DECOY THERAPEUTICS INC's EBITDA?

DECOY THERAPEUTICS INC (DCOY) had EBITDA of -$12.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is DECOY THERAPEUTICS INC's return on equity (ROE)?

DECOY THERAPEUTICS INC (DCOY) has a return on equity of 212.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is DECOY THERAPEUTICS INC's free cash flow?

DECOY THERAPEUTICS INC (DCOY) generated -$5.4M in free cash flow during fiscal year 2025. This represents a -19.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is DECOY THERAPEUTICS INC's operating cash flow?

DECOY THERAPEUTICS INC (DCOY) generated -$4.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are DECOY THERAPEUTICS INC's total assets?

DECOY THERAPEUTICS INC (DCOY) had $11.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are DECOY THERAPEUTICS INC's capital expenditures?

DECOY THERAPEUTICS INC (DCOY) invested $577K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does DECOY THERAPEUTICS INC spend on research and development?

DECOY THERAPEUTICS INC (DCOY) invested $368K in research and development during fiscal year 2025.

How many shares does DECOY THERAPEUTICS INC have outstanding?

DECOY THERAPEUTICS INC (DCOY) had 8,006 shares outstanding as of fiscal year 2025.

What is DECOY THERAPEUTICS INC's current ratio?

DECOY THERAPEUTICS INC (DCOY) had a current ratio of 2.13 as of fiscal year 2025, which is generally considered healthy.

What is DECOY THERAPEUTICS INC's debt-to-equity ratio?

DECOY THERAPEUTICS INC (DCOY) had a debt-to-equity ratio of 0.88 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is DECOY THERAPEUTICS INC's return on assets (ROA)?

DECOY THERAPEUTICS INC (DCOY) had a return on assets of 113.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is DECOY THERAPEUTICS INC's cash runway?

Based on fiscal year 2025 data, DECOY THERAPEUTICS INC (DCOY) had $10.7M in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 27 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is DECOY THERAPEUTICS INC's Piotroski F-Score?

DECOY THERAPEUTICS INC (DCOY) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are DECOY THERAPEUTICS INC's earnings high quality?

DECOY THERAPEUTICS INC (DCOY) has an earnings quality ratio of -0.39x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.